Clinical Trial Update: A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating WSD0922-FU in patients with EGFR-mutant, advanced non-small cell lung cancer is ongoing and currently recruiting. The spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• WSD0922-FU (WSD0922-FU)

Snippet

Sponsor: Wayshine Biopharm, Inc. | Conditions: EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING